Scientia Advisors in the News

---

Publications

---

Press Releases

---

Events

---

Luminary Insights

---

Media Contact

---

Scientia Advisors in the News

Pharmalot: "Generic Lovenox & An FDA Precedent: Scientia Advisors' Jonathan Pan Explains"

Ed Silverman
July 30th, 2010

Last week, the FDA issued one of those surprise product approvals by giving a thumbs up to a generic version of Lovenox, a widely used bloodthinner sold by Sanofi-Aventis, much sooner than most people expected. The move is something of a game-changer for the pharmaceutical industry and Jonathan Pan, senior associate at Scientia Advisors, speaks briefly about the implications.

Read the full article at: Pharmalot